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1137-102 Influence of Microsomal Triglyceride Transfer Protein - 
493G/T Polymorphism on Cardiovascular Events After 
Myocardial Infarction in Diabetic Patients
Hiroya Mizuno, Hiroshi Sato, Kunihiro Kinjo, Daisaku Nakatani, Masahiko Shimizu, 
Masatsugu Hori, Osaka University Graduate School of Medicine, Osaka, Japan
BACKGROUND. Microsomal triglyceride transfer protein (MTP) transfers lipids onto apo-
lipoprotein (Apo) B which is the major protein component of low density lipoprotein.
According to previous reports focused on a functional, non-coding MTP -493G/T poly-
morphism, the relationship between the polymorphism and lipid profiles, visceral obesity
and the incidence of coronary heart disease is not fully elucidated. Furthermore, the
minor -493TT genotype was reported to be associated with a higher concentration of
small dense LDL-III subfraction in type 2 diabetic patients. Thus, we hypothesized that
the MTP -493G/T polymorphism is associated with cardiovascular events after myocar-
dial infarction(MI) in patients with diabetes mellitus. METHODS. To test our hypothesis,
we genotyped consecutive 375 diabetic patients with acute myocardial infarction who
registered Osaka Acute Coronary Insufficiency Study since April 1999 to compare the
incidence of cardiovascular events defined as composite of death, MI, unstable angina,
heart failure, life-threatening arrhythmia and cereberal infarction. RESULTS. Overall gen-
otype frequency was: GG,71.4% ; GT, 24.2% ; TT, 4.4%. No significant difference was
observed between the group of T allele carriers (GT+TT group) and G allele homozy-
gotes (GG group) in clinical characteristics, conventional coronary risk factors and thera-
pies. During mean follow-up period of 488 days, cardiovascular event rate in the GT+TT
group was significantly higher than the GG group (19.1% vs. 8.7%, log rank; p=0.0028).
By multivariate analysis, T allele remained as an independent predictor of cardiovascular
events with respective Odds ratio of 3.05 (95% CI 1.28-7.26, p=0.012). CONCLUSION.
MTP -493TT polymorphism is independently associated with worse cardiovascular out-
comes after MI in diabetic patients. Screening of this polymorphism may provide further
information.
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1154-85 High Incidence of the Metabolic Syndrome in 
Symptomatic Coronary Heart Disease in North America 
During the Early 21st Century
William E. Boden, Robert A. O'Rourke, William S. Weintraub, Koon Teo, Pamela 
Hartigan, David J. Maron, William Kostuk, Karen Potter, Paul Casperson, for the 
COURAGE Trial Investigators, Hartford Hospital, Hartford, CT
Background: Both the prevalence and incidence of the Metabolic Syndrome (TMS)
appear to be rising during the last decade, but there are few studies that quantify the
occurrence rate of TMS in patients with symptomatic coronary heart disease (CHD). The
ongoing Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
(COURAGE) Trial is designed to compare percutaneous coronary intervention plus
aggressive medical therapy vs. medical therapy alone on death/MI in CHD patients dur-
ing a 3-7 year follow-up. From mid-1999 to the present, 2,071 patients have been
enrolled and 944 (46%) have met the NCEP-III definition of TMS at trial entry.
Methods: All patients were divided into 2 groups (with/without TMS) and Chi-Square
tests were performed to assess between-group differences for selected baseline charac-
teristics: age (> 62 years), sex, prior revascularization (Revasc), reversible stress myo-
cardial perfusion imaging (MPI) defects, multi-vessel (MV) CAD, and CCS anginal class
>3.
Results: see the Table. 
Conclusion: TMS is a common disorder among CHD patients randomized to the COUR-
AGE Trial in North America. Compared to patients without TMS, CHD patients with TMS
are younger, more commonly female, have a higher incidence of prior revascularization,
reversible MPI defects, multivessel CAD and higher CCS anginal class. These data sug-
gest that CHD patients with TMS may be at higher risk for recurrent cardiac events and
may warrant more aggressive evaluation and management.
1154-86 Hyperglycaemia Reduces Myocardial Reperfusion 
During Primary Percutaneous Coronary Intervention for 
ST-Elevation Myocardial Infarction
Jorik Timmer, Jan Paul Ottervanger, Arnoud WJ van 't Hof, Jan CA Hoorntje, Menko-Jan 
de Boer, Harry Suryapranata, Felix Zijlstra, The Zwolle Myocardial Infarction Study 
Group, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
Background: Patients with hyperglycaemia on admission have an adverse prognosis
after ST-segment elevation myocardial infarction (STEMI). However, the causal link
between disturbances in glucose metabolism and outcome is unclear.
Methods: We investigated whether admission hyperglycaemia in STEMI patients treated
with primary percutaneous coronary intervention (PCI) was associated with reduced
myocardial reperfusion as documented by ST segment resolution and myocardial blush
grade. We also studied the influence of reduced myocardial reperfusion on clinical out-
come, including enzymatic infarct size (LDHq72), left ventricular ejection fraction (LVEF)
and mortality.
Results: In total, 383 consecutive patients were included in this study. Patients with
hyperglycaemia had more often a reduced myocardial blush grade (25% vs. 13%,
p=0.01) and incomplete ST segment resolution (59% vs. 36%, p<0.001) compared to
patients without hyperglycaemia on admission. Patients with reduced myocardial reperfu-
sion had larger infarct sizes (678±665 vs. 444±302 U/L, p<0.01), more reduced left ven-
tricular function (37.6±11.9% vs. 43.8±11.5%, p=0.02) and higher mortality (8% vs. 4%,
p=0.38). Multivariate analyses did not change these findings.
Conclusion: Hyperglycaemia on admission is independently associated with both
incomplete ST segment resolution and reduced myocardial blush after primary PCI.
These signs of reduced myocardial reperfusion were associated with an adverse clinical
outcome.
1154-87 Low Incidence of Coronary Microembolization During 
Recanalization of Chronic Total Coronary Occlusions
Philipp Bahrmann, Michael Jantz, Gerald S. Werner, Hans R. Figulla, Friedrich-Schiller-
University, Jena, Germany
Introduction: After a percutaneous coronary intervention (PCI) an elevation of cardiac
marker enzymes as an indicator of distal macro- or microembolization is observed in 10
to 30%. Consequently adjunctive therapies such as GP IIb/IIIa antagonists are applied,
and distal protection devices are under investigation for specific types of lesions. In view
of the often long and diffuse lesions of chronic total coronary occlusions (CTOs) with their
maximum plaque load of organized thrombotic material these lesions could represent
such a high risk lesion group. However, there are no systematic data available on the inci-
dence of cardiac marker enzyme elevations after recanalization of a CTO.
Methods: In 121 consecutive patients (age 64±10 years) a CTO (duration>2 weeks,
median 3 months) was successfully recanalized with stent implantation in all lesions.
Over a period of 24 hours after PCI, creatine kinase (CK; upper limit of normal [ULN] for
women 1.17 mol/L/s, for men 1.33 mol/L/s) and cardiac troponin I (cTNI; threshold 0.1
ng/mL) were studied. Biplane left ventricular angiograms were obtained and the regional
wall motion was assessed with the wall motion severity index (WMSI). Patients were
divided in 55 patients with either a normal or moderately impaired regional function
(group N: WMSI>-2 SD /chord) and in 66 patients with a severely impaired regional func-
tion (group A: WMSI<-2 SD/chord).
Results: A CK and/or cTNI elevation after recanalization of a CTO was observed in only 9
patients (8%). in 8 of 9 patients the elevation of CK was mild with an increase of one time
of the ULN, in one patient it was twice the ULN. The incidence of a cardiac marker
enzyme elevation was similar in group N and in group A, indicating that the low incidence
was not due to a high prevalence of akinetic or nonvital myocardium.
Conclusion: Despite the high plaque load of organized thrombotic material in CTOs, the
incidence of cardiac marker enzyme elevations is very low after a recanalization. Specific
adjunctive medical or interventional therapy may not be required during recanalization of
a CTO, in contrast to acute coronary occlusions.
1154-89 Multicenter Study of Safety and Efficacy of a Biphasic 
Impedance-Compensating Waveform for Transthoracic 
Defibrillation
Randall Fincke, Charles I. Haffajee, David M. Barash, Francesco Fedele, Henry R. 
Halperin, Johns Hopkins University Hospital, Baltimore, MD, St. Elizabeth's Medical 
Center, Boston, MA
Background:An automated external defibrillator (AED) can reduce the time delay in
defibrillation. With delivery of fixed amounts of energy, peak leading edge current can be
excessive (> 50 amps) if transthoracic impedance is low. These peak currents can pro-
duce myocardial dysfunction. At lower energy settings, average current may not be ade-
quate for reliable defibrillation if transthoracic impedance in high. We developed a new
AED that uses integrated electronics, 200uF capacitors, and microprocessor-controlled
impedance compensation to: (1) reduce the total AED weight to 2.8 lbs. from the 6 lbs. of
previous AEDs; (2) limit peak leading edge current to 30 amps in patients with low imped-
ance; and (3) deliver a first phase average current of 16 amps in patients with high
impedance. Full energy is delivered in these latter patients by extending the pulse dura-
tion and utilizing the lower tilt enabled by the increased capacitance. We previously
showed the benefit of this waveform in animals. This study was designed to test the clini-
cal safety and efficacy of this innovative waveform in humans with ventricular fibrillation.
Methods: In this prospective study, 60 patients undergoing ICD implant or testing had
ventricular fibrillation induced. Each was defibrillated at the lowest device energy setting
(200J).
Results: All 60 patients (100%) were successfully defibrillated on the first administered
shock. The average transthoracic impedance was 80 ohms (range 42-122). The mean
first phase average current was 17 amps (range 12-25) and the mean first phase peak
TMS Age>62 Female Prior Revasc MPI defects MV-CAD CCS > 3
Yes 43% 17% 26% 94% 73% 25%
No 50% 12% 21% 91% 67% 21%
P value <0.01 <0.01 <0.01 0.01 <0.01 0.01
